Repatha (evolocumab) 140 мг; syringes №2

Indications

Hypercholesterolemia and Mixed Dyslipidemia

Repatha is indicated for adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia as an adjunct to diet:in combination with a statin or a statin and other lipid-lowering therapies for patients unable to achieve target LDL-C levels with the maximum tolerated statin dose, oralone or in combination with other lipid-lowering therapies for patients who are statin intolerant or for whom statins are contraindicated.

Homozygous Familial Hypercholesterolemia

Repatha is indicated for adults and adolescents aged 12 years and older with homozygous familial hypercholesterolemia in combination with other lipid-lowering therapies.

 Established cardiovascular atherosclerosis

Repatha is indicated for adults with established cardiovascular atherosclerosis (myocardial infarction, stroke, or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL cholesterol levels, as an adjunct to other risk factor management:in combination with the maximum tolerated dose of a statin, with or without other lipid-lowering therapies, oalone or in combination with other lipid-lowering therapies in patients intolerant to statins or in patients for whom statins are contraindicated.